risperidon mylan 3 mg filmom obložene tablete
mylan hrvatska d.o.o., koranska 2, zagreb - risperidonum - filmom obložena tableta - 3 mg - urbroj: jedna filmom obložena tableta sadrži 3 mg risperidona
risperidon mylan 4 mg filmom obložene tablete
mylan hrvatska d.o.o., koranska 2, zagreb - risperidonum - filmom obložena tableta - 4 mg - urbroj: jedna filmom obložena tableta sadrži 4 mg risperidona
nimulid 100 mg/1 tableta tableta
amicus pharma d.o.o. - nimesulid - tableta - 100 mg/1 tableta - 1 tableta sadrži: 100 mg nimesulid
letrox 100 100 µg/1 tableta tableta
berlin chemie / menarini bh d.o.o. sarajevo - levotiroksinnatrijum - tableta - 100 µg/1 tableta - 1 tableta sadrži: 100 mcg levotiroksinnatrijum
letrox 150 150 µg/1 tableta tableta
berlin chemie / menarini bh d.o.o. sarajevo - levotiroksinnatrijum - tableta - 150 µg/1 tableta - 1 tableta sadrži: 150 mcg levotiroksinnatrijum
letrox 100 100 µg/1 tableta tableta
berlin chemie / menarini bh d.o.o. sarajevo - levotiroksinnatrijum - tableta - 100 µg/1 tableta - 1 tableta sadrži: 100 mcg levotiroksinnatrijum
letrox 150 150 µg/1 tableta tableta
berlin chemie / menarini bh d.o.o. sarajevo - levotiroksinnatrijum - tableta - 150 µg/1 tableta - 1 tableta sadrži: 150 mcg levotiroksinnatrijum
letrox 50 50 µg/1 tableta tableta
berlin chemie / menarini bh d.o.o. sarajevo - levotiroksinnatrijum - tableta - 50 µg/1 tableta - 1 tableta sadrži: 50 mcg levotiroksinnatrijum
nimulid 100 mg/1 tableta tableta
amicus pharma d.o.o. - nimesulid - tableta - 100 mg/1 tableta - 1 tableta sadrži: 100 mg nimesulida
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastična sredstva - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.